

Resource Summary Report

Generated by [dkNET](#) on Jul 31, 2026

PD-L1 (E1L3N) XP Rabbit Antibody

RRID:AB_2687655

Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 13684, RRID:AB_2687655)

Antibody Information

URL: http://antibodyregistry.org/AB_2687655

Proper Citation: (Cell Signaling Technology Cat# 13684, RRID:AB_2687655)

Target Antigen: PD-L1

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: WB, IP, IHC-Bond, IHC-P, FC-FP

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: PD-L1 (E1L3N) XP Rabbit Antibody

Description: This recombinant monoclonal targets PD-L1

Target Organism: human

Clone ID: Clone E1L3N®

Antibody ID: AB_2687655

Vendor: Cell Signaling Technology

Catalog Number: 13684

Record Creation Time: 20260729T221927+0000

Record Last Update: 20260729T221927+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for PD-L1 (E1L3N) XP Rabbit Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 150 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Huyghe N, et al. (2025) Impact of the tumor immune contexture in microsatellite-stable metastatic colorectal cancer treated with avelumab, cetuximab, and irinotecan. Cell reports. Medicine, 6(7), 102201.

Zhao Y, et al. (2025) A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression. Cancer research, 85(18), 3399.

Hirade K, et al. (2025) Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy. Cell reports. Medicine, 6(9), 102317.

Suzuki H, et al. (2025) GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression. Cancer research communications, 5(9), 1530.

Berry D, et al. (2025) The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma. Cell reports, 44(3), 115365.

Wang L, et al. (2025) ANLN promotes head and neck squamous cell carcinoma progression by upregulating PD-L1 via the ERK-MAPK pathway. iScience, 28(2), 111633.

Thomas-Jardin S, et al. (2025) The Integrated Stress Response Pathway Coordinates Translational Control of Multiple Immune Checkpoints in Lung Cancer. Cancer research, 85(14), 2574.

Bach CA, et al. (2025) A novel sialylation pathway mediated by extracellular vesicles in aggressive prostate cancer. PloS one, 20(9), e0329014.

Schiantarelli J, et al. (2025) Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma. *Cancer cell*, 43(2), 308.

Shao N, et al. (2025) USP5 stabilizes YTHDF1 to control cancer immune surveillance through mTORC1-mediated phosphorylation. *Nature communications*, 16(1), 1313.

Hemida N, et al. (2025) Unlocking the potential of novel tetrahydro- β -carboline-based HDAC6 inhibitors for colorectal cancer therapy: Design, synthesis and biological evaluation. *Bioorganic chemistry*, 160, 108454.

Shao YY, et al. (2025) Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma. *Biology direct*, 20(1), 49.

Tiburcio PDB, et al. (2025) PD-L1 Expression is Mediated by microRNA Processing, Wnt/ β -Catenin Signaling, and Chemotherapy in Wilms Tumor. *Pediatric blood & cancer*, 72(9), e31852.

Robinson SI, et al. (2025) Oncolytic measles virotherapy encoding the neutrophil-activating protein is effective in synovial sarcoma. *Molecular therapy. Oncology*, 33(4), 201062.

Cigrang M, et al. (2025) Pan-inhibition of super-enhancer-driven oncogenic transcription by next-generation synthetic ecteinascidins yields potent anti-cancer activity. *Nature communications*, 16(1), 512.

Oka T, et al. (2025) Langerhans Cells Directly Interact with Resident T Cells in the Human Epidermis. *JID innovations : skin science from molecules to population health*, 5(1), 100324.

Möhrmann L, et al. (2025) Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors. *Med (New York, N.Y.)*, 6(6), 100612.

Morris VK, et al. (2025) Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(9), 1657.

Xing YL, et al. (2025) BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAFV600E-mutant glioma. *Cell reports. Medicine*, 6(6), 102183.

Li HS, et al. (2025) RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations. *Cell reports. Medicine*, 6(7), 102235.